Does heparin prophylaxis prevent exacerbations of hereditary angioedema?

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 6, 2002, Pages 995-1000

  Weiler, John M ^a   Quinn, Susan A ^a   Woodworth, George G ^a   Brown, Donald D ^a   Layton, Teresa A ^a   Maves, Karen K ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

C1 esterase inhibitor; Heparin; Hereditary angioedema

Indexed keywords

HEPARIN; PLACEBO;

ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TRACT; HUMAN; INJECTION PAIN; MALE; MUCOSA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SKIN;

EID: 0036279878     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.124892     Document Type: Article

References (39)

1. Hereditary angioedema: The clinical syndrome and its management
2. C1 INH deficiency and angioedema: A spectrum of disease
3. C1 inhibitor and hereditary angioneurotic edema
4. C1 esterase inhibitor deficiency, airway compromise, and anesthesia
5. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations
6. Hereditary angioedema: A decade of management with stanozolol
7. Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience
8. C1 INH concentrate in the therapy of hereditary angioedema
9. Inhaled heparin in the treatment of hereditary angioedema
10. Possible efficacy of nebulized heparin therapy in hereditary angioedema
11. Anticomplementary power of heparin
12. Heparin binding and augmentation of C1 inhibitor activity
13. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis by polyanions and polycations
14. Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement
15. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-1: Effect on fluid phase C1 and on C1 bound to EA or to EAC4
16. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-II: Effect of polyanions on the binding of C2 to EAC4b
17. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-III: Inhibition of C4 and C2 binding site(s) on C1s by polyanions
18. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin
19. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase
20. Small heparin fragments regulate the amplification pathway of complement
21. Potentiation of factor H by heparin: A rate-limiting mechanism for inhibition of the alternative complement pathway
22. Discrimination between activators and nonactivators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site on factor H
23. Localization of the heparin-binding site on complement factor H
24. Heparin is not just an anticoagulant anymore: Six and one half decades of studies on the ability of heparin to regulate complement activity
25. Asymmetric distribution of sites with high affinity for antithrombin III in rat skin heparin proteoglycans
26. Heparin: An old drug with a new paradigm
27. Structure and biological activity of heparin
28. Some recent developments in the pharmacology of heparin
29. Heparin: An important drug enters its seventh decade
30. Potentiation of C1-esterase inhibitor activity by heparin
31. Inactivator of the first component of human complement (CIINA): Enhancement of CIINA activity against C1s by acidic mucopolysaccharides
32. A postulated mechanism for heparin's potentiation of C1 inhibitor function
33. Heparin and modified heparin inhibit complement activation in vivo
34. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum
35. Hereditary angioedema and heparin therapy
36. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s
37. Kinetics of interaction of C1 inhibitor with complement C1s
38. C1 inhibitor: Different mechanisms of reaction with complement component C1 and C1s
39. Limitations of established antithrombotic strategies